Celyad Oncology Sa's

• CYAD's Stock Performance relative to its Competitors

Verastem Inc Share Performance -7.58% Over The Past 5 Days

Verastem Inc Profile Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics. More about Verastem Inc 's Market Share

Ovid Therapeutics Inc Share Performance +50.28% This Year

Ovid Therapeutics Inc Profile Ovid Therapeutics Inc's business model is focused on developing and commercializing innovative medicines for the treatment of rare neurological disorders. More about Ovid Therapeutics Inc 's Market Share

Oncosec Medical Incorporated Share Performance -45.66% 30 Days

Oncosec Medical Incorporated Profile Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers. More about Oncosec Medical Incorporated's Market Share

Oncorus Inc Share Performance +401.99% This Quarter

Oncorus Inc Profile Oncorus Inc is a biotechnology company that specializes in developing next-generation viral immunotherapies to treat various types of cancers. Their business model revolves around leveraging the power of oncolytic viruses, which selectively target and destroy cancer cells while stimulating an immune response against the tumor. Oncorus focuses on rigorous research, clinical development, and potential partnerships to advance their innovative therapies towards commercialization and widespread patient access. More about Oncorus Inc 's Market Share

Nuvectis Pharma inc Share Performance +134.18% This Quarter

Nuvectis Pharma inc Profile Nuvectis Pharma Inc's business model appears to focus on the development and commercialization of pharmaceutical products. More about Nuvectis Pharma inc 's Market Share

Sources: Celyad Oncology Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 10:23 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Celyad Oncology Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.